A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery
Open Access
- 1 June 2007
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (8), 1660-1665
- https://doi.org/10.1111/j.1538-7836.2007.02644.x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip ReplacementCirculation, 2006
- Comparison of Fondaparinux and Enoxaparin in Acute Coronary SyndromesNew England Journal of Medicine, 2006
- BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJournal of Thrombosis and Haemostasis, 2005
- Prevention of Venous ThromboembolismChest, 2004
- Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary EmbolismNew England Journal of Medicine, 2003
- Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic SurgeryA Meta-analysis of 4 Randomized Double-blind StudiesArchives of Internal Medicine, 2002
- Fondaparinux, a Synthetic Pentasaccharide: The First in a New Class of Antithrombotic Agents — The Selective Factor Xa InhibitorsCardiovascular Drug Reviews, 2002
- Risk of and Prophylaxis for Venous Thromboembolism in Hospital PatientsPhlebology: The Journal of Venous Disease, 1998
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- Roentgen Diagnosis of Venous Thrombosis in the LegArchives of Surgery, 1972